Protocol for the development and validation of a trigger tool for antiretroviral ADE detection among adult HIV/AIDS patients: A short communication
Fuente:
Zenodo
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Recurso digital |
| Langue: | anglais |
| Publié: |
Zenodo
2024
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866901846656811008 |
|---|---|
| author | Amaka Yves-Ann Ezeuko Sunday Odunke Nduka Chioma Callista Ezeuko Angus Nnamdi Oli Obinna Ikechukwu Ekwunife |
| author_facet | Amaka Yves-Ann Ezeuko Sunday Odunke Nduka Chioma Callista Ezeuko Angus Nnamdi Oli Obinna Ikechukwu Ekwunife |
| contents | <div>Antiretroviral therapy (ART) is a lifelong combination therapy which has been very promising in managing HIV/AIDs but reported to have several adverse events on the recipients, affecting the desired antiretroviral therapeutic goals. Adverse drug event detection and prevention therefore become very important safety culture maintenance tools among patients living with HIV/AIDS. The designed protocol provided step by step approaches to develop and validate a trigger tool for detection of adverse drug events (ADE) among adult HIV/AIDS patients. The approaches involved include a baseline (Pre-trigger tool development) retrospective clinical record review to establish a baseline ADE detection capacity of a conventional non-trigger tool method; the Delphi panel process to develop the trigger tool in question; Face and content validity approach for validation of the developed trigger tool; Pilot test of the trigger tool using small clinical record sample; determining the effectiveness of the developed trigger tool through the retrospective clinical record review of same samples reviewed at the baseline. Finally, the protocol described the process of determining the feasibility of the developed trigger tool through the survey of the clinical record review team members.</div> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_14665645 |
| institution | Zenodo |
| language | eng |
| publishDate | 2024 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Protocol for the development and validation of a trigger tool for antiretroviral ADE detection among adult HIV/AIDS patients: A short communication Amaka Yves-Ann Ezeuko Sunday Odunke Nduka Chioma Callista Ezeuko Angus Nnamdi Oli Obinna Ikechukwu Ekwunife Protocol Trigger tool Development Validation Adverse drug event HIV Patients <div>Antiretroviral therapy (ART) is a lifelong combination therapy which has been very promising in managing HIV/AIDs but reported to have several adverse events on the recipients, affecting the desired antiretroviral therapeutic goals. Adverse drug event detection and prevention therefore become very important safety culture maintenance tools among patients living with HIV/AIDS. The designed protocol provided step by step approaches to develop and validate a trigger tool for detection of adverse drug events (ADE) among adult HIV/AIDS patients. The approaches involved include a baseline (Pre-trigger tool development) retrospective clinical record review to establish a baseline ADE detection capacity of a conventional non-trigger tool method; the Delphi panel process to develop the trigger tool in question; Face and content validity approach for validation of the developed trigger tool; Pilot test of the trigger tool using small clinical record sample; determining the effectiveness of the developed trigger tool through the retrospective clinical record review of same samples reviewed at the baseline. Finally, the protocol described the process of determining the feasibility of the developed trigger tool through the survey of the clinical record review team members.</div> |
| title | Protocol for the development and validation of a trigger tool for antiretroviral ADE detection among adult HIV/AIDS patients: A short communication |
| topic | Protocol Trigger tool Development Validation Adverse drug event HIV Patients |
| url | https://doi.org/10.5281/zenodo.14665645 |